- PharmAla Biotech (MDMA) and its manufacturing partners have received an export permit for 300 grams of its LaNeo MDMA
- PharmAla believes this is the largest single Health Canada export permit ever granted
- Nicholas Kadysh, CEO of PharmAla, met with Sabrina Cuthbert to discuss the news
- PharmAla (MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA
- Pharmala Biotech Holdings Inc. (MDMA) opened trading at C$0.045
PharmAla Biotech (MDMA) and its manufacturing partners have received an export permit for 300 grams of its LaNeo MDMA.
PharmAla believes this is the largest single Health Canada export permit ever granted by weight to date.
Nicholas Kadysh, CEO of PharmAla, met with Sabrina Cuthbert to discuss the news.
“We’re incredibly proud of this milestone. It is additional proof that the clinical development of MDMA is moving forward. PharmAla exists to assist our client researchers around the world by not only saying we’ll provide them with research materials but actually delivering. The global psychedelics industry is still in its infancy, but strong demand for these molecules helps ensure a foundational role for manufacturers like PharmAla.”
PharmAla (MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX-class molecules, including MDMA.
Pharmala Biotech Holdings Inc. (MDMA) opened trading at C$0.045.
